DE1265758B - Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts - Google Patents

Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts

Info

Publication number
DE1265758B
DE1265758B DES68684A DES0068684A DE1265758B DE 1265758 B DE1265758 B DE 1265758B DE S68684 A DES68684 A DE S68684A DE S0068684 A DES0068684 A DE S0068684A DE 1265758 B DE1265758 B DE 1265758B
Authority
DE
Germany
Prior art keywords
salts
phenyl
acid addition
addition salts
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DES68684A
Other languages
German (de)
Inventor
Gianfranco Di Paco
Sonnino Celesio Tauro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorio Guidotti SpA
Original Assignee
Laboratorio Guidotti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Guidotti SpA filed Critical Laboratorio Guidotti SpA
Priority to DES68684A priority Critical patent/DE1265758B/en
Publication of DE1265758B publication Critical patent/DE1265758B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton

Description

BUNDESREPUBLIK DEUTSCHLANDFEDERAL REPUBLIC OF GERMANY

DEUTSCHESGERMAN

PATENTAMTPATENT OFFICE

AUSLEGESCHRIFTEDITORIAL

Int. Cl.:Int. Cl .:

C07cC07c

Deutsche KL: 12 q-32/20 German KL: 12 q- 32/20

Nummer: 1265 758Number: 1265 758

Aktenzeichen: S 68684IV b/12 qFile number: S 68684IV b / 12 q

Anmeldetag: 25. Mai 1960 Filing date: May 25, 1960

Auslegetag: 11. April 1968Open date: April 11, 1968

Die Erfindung betrifft ein Verfahren zur Herstellung von ο - - Dialkylaminoäthoxy) - phenylketonen der allgemeinen FormelThe invention relates to a process for the preparation of ο - - dialkylaminoethoxy) phenyl ketones of the general formula

OR'OR '

worin R den Methyl-, den ß-Phenyläthyl- oder den a-Phenyl-n-propylrest und R' den /J-Dimethylaminoäthyl- oder den /5-Diäthylaminoäthylrest bedeutet, und deren Säureadditionssalzen und quartären Salzen.wherein R denotes the methyl, the ß-phenylethyl or the a-phenyl-n-propyl radical and R 'den / J-dimethylaminoethyl or denotes the / 5-diethylaminoethyl radical, and their acid addition salts and quaternary salts.

Das erfindungsgemäße Verfahren ist dadurch gekennzeichnet, daß man in an sich bekannter Weise entsprechende /ί-Dialkylaminoäthylhalogenide oder deren halogenwasserstoffsaure Salze mit den entsprechenden o-Hydroxy-phenylketonen umsetzt und die erhaltenen Basen gegebenenfalls in Säureadditionssalze oder quartäre Salze überführt.The inventive method is characterized in that one known per se Way corresponding / ί-Dialkylaminoäthylhalogenide or the hydrohalic acid salts thereof are reacted with the corresponding o-hydroxyphenyl ketones and the bases obtained are optionally converted into acid addition salts or quaternary salts.

Die Umsetzung wird in organischen Lösungsmitteln, wie z. B. Benzol, Toluol oder Xylol, vorgenommen. Sie kann in Gegenwart oder in Abwesenheit von Halogenwasserstoffakzeptoren stattfinden, z. B. wasserfreien Alkalicarbonaten oder Pyridin.The reaction is carried out in organic solvents, such as. B. benzene, toluene or xylene made. It can take place in the presence or absence of hydrogen halide acceptors, z. B. anhydrous alkali carbonates or pyridine.

Die erfindungsgemäß hergestellten Äther bilden mit anorganischen Säuren, wie Salzsäure, Additionssalze. Diese Salze können durch Einwirkung der Säuren auf die in geeigneten Lösungsmitteln, wie Äthyläther, gelösten Basen erlangt werden. Durch Reaktion mit quartären Verbindungen bildenden Mitteln, wie Alkylhalogeniden, z. B. Methylbromid, Äthyljodid u. dgl., lassen sich quartäre Ammoniumverbindungen herstellen.The ethers prepared according to the invention form addition salts with inorganic acids such as hydrochloric acid. These salts can by the action of the acids in suitable solvents, such as Ethyl ether, dissolved bases can be obtained. Forms by reaction with quaternary compounds Agents such as alkyl halides, e.g. As methyl bromide, ethyl iodide and the like, quaternary ammonium compounds can be used produce.

Im Gegensatz zu den gemäß den bisherigen Erkenntnissen für die neuen Verbindungen zu erwartenden Wirkungen zeigen diese eine erhebliche und sehr selektive kranzadernerweiternde Wirkung neben einer guten krampfstillenden Wirkung. Überraschenderweise zeigen die erfindungsgemäß her-. gestellten Verbindungen, bei welchen die Öxydiäthylaminoalkylkette in Ortho-Stellung zum Ketonradikal angeordnet ist, eine bedeutend größere Wirkung als Verbindungen, bei denen die Alkylkctte. und das. Ketonradikal in Para-Stellung stehen. Unter den untersuchten Verbindungen hat sich das o»0?-Diäthylaminoäthoxy)-phenylpropiophenon-Chlorhydrat als besonders wirksam erwiesen. Auf einem isolierten Säugetierherz nach Langendorff erwies sich Verfahren zur Herstellung von
o-(/}-Dialkylaminoäthoxy)-phenylketonenund
deren Säureadditionssalzen und quartären Salzen
In contrast to the effects to be expected according to the previous knowledge for the new compounds, these show a considerable and very selective coronary vein widening effect in addition to a good anticonvulsant effect. Surprisingly, show the invention. Compounds in which the Öxydiethylaminoalkylkette is arranged in the ortho position to the ketone radical have a significantly greater effect than compounds in which the Alkylkctte. and that. Ketone radicals are in para position. Among the compounds examined, the o »0? -Diethylaminoethoxy) phenylpropiophenone chlorohydrate has proven to be particularly effective. On an isolated mammalian heart according to Langendorff, a method for the production of
o - (/} - dialkylaminoethoxy) phenyl ketones and
their acid addition salts and quaternary salts

Anmelder:Applicant:

S. p. A. Laboratorio Guidotti&C, Pisa (Italien)P. A. Laboratorio Guidotti & C, Pisa (Italy)

Vertreter:Representative:

Dr.-Ing. E. HoffmannDr.-Ing. E. Hoffmann

und Dipl.-Ing. W. Eitle, Patentanwälte,and Dipl.-Ing. W. Eitle, patent attorneys,

8000 München 8, Maria-Theresia-Str. 68000 Munich 8, Maria-Theresia-Str. 6th

Als Erfinder benannt:Named as inventor:

Gianfranco Di Paco,Gianfranco Di Paco,

Sonnino Celesio Tauro, Pisa (Italien)Sonnino Celesio Tauro, Pisa (Italy)

diese Verbindung bei einer molaren Konzentration von 2 · 1O-6 als wenig giftig (DL50 bei einer Ratte per os eingenommen 156 mg/kg) und zeigte keinerlei unerwünschte Nebenwirkungen zu Lasten des Arteriendruckes, so daß seine Anwendung in der menschlichen Therapie als der Aderverengung entgegenwirkendes Mittel empfohlen werden konnte.this compound at a molar concentration of 2 · 10 -6 was considered to be less toxic (DL50 taken per os in a rat 156 mg / kg) and did not show any undesirable side effects at the expense of arterial pressure, so that its use in human therapy as a counteracting vein constriction Funds could be recommended.

Beispiel 1example 1

500 cm3 Toluol mit 37 g wasserfreiem Kaliumkarbonat K2CO3, 0,1 Mol o-Hydroxy-3-phenyI-propiophenon und 0,35 Mol ß-Dimethylaminoäthylchlorid wurden unter Rückfluß zum Sieden gebracht; das Gemisch wurde abgekühlt und gefiltert, nach Abdestillation des Lösungsmittels kristallisiert und der Rückstand nach Lösung in Äther und Wiederausfallung durch Zusatz von Petroläther gereinigt; das so erhaltene o-(/S-Dimethylaminoäthoxy)-3-phenyl-propiophenon schmilzt bei 500C.500 cm 3 of toluene with 37 g of anhydrous potassium carbonate K2CO3, 0.1 mol of o-hydroxy-3-phenyI-propiophenone and 0.35 mol of β-dimethylaminoethyl chloride were brought to the boil under reflux; the mixture was cooled and filtered, crystallized after distilling off the solvent and the residue was purified after dissolution in ether and reprecipitation by adding petroleum ether; the thus obtained o - (/ S-Dimethylaminoäthoxy) -3-phenyl-propiophenone melts at 50 0 C.

Beispiel 2Example 2

0,1 Mol ο - Hydroxy - 3 - phenyl - propiophenon, 0,25 Mol ß-Chloräthyldiäthylamino-chlorhydrat und 40 g wasserfreies Kaliumkarbonat K2CO3 wurden in 500 cm3 Toluol unter Rückfluß und unter Umrühren so lange auf Siedetemperatur erhitzt, bis eine Probe einer mit Äthanol verdünnten Toluollösung mit einem Tropfen Ferrichloridlösung keine Farbreaktion mehr ergab.0.1 mol of ο-hydroxy-3-phenyl-propiophenone, 0.25 mol of ß-chloroethyl diethylamino-chlorohydrate and 40 g of anhydrous potassium carbonate K2CO3 were refluxed in 500 cm 3 of toluene with stirring until a sample of one toluene solution diluted with ethanol with a drop of ferric chloride solution no longer gave any color reaction.

Nach Abkühlung wurde die Mischung gefiltert, das Lösungsmittel durch Destillation entfernt und der Rest bei herabgesetztem Druck fraktioniert.After cooling, the mixture was filtered, the solvent removed by distillation and the rest fractionated at reduced pressure.

809534/530809534/530

IOIO

1515th

2020th

Die erhaltene Fraktion siedet bei 264 bis 268° C bei einem Druck von 30 mm Hg-Säule und entspricht dem o-(/?-Diäthylaminoäthoxy)-3-phenyl-pro-* piophenon.The fraction obtained boils at 264 to 268 ° C. at a pressure of 30 mm Hg column and corresponds to the o - (/? - diethylaminoethoxy) -3-phenyl-propiophenone.

B ei spi el 3Example 3

0,1 Mol o-Hydroxy-w-phenyl-w-äthylacetophenonnatriumsalz und 0,2MoI /J-chloräthyldiäthylamin wurden auf Siedetemperatur gebracht und etwa 2 Stunden auf dieser Temperatur gehalten. Nach Zugabe von 250 cm3 Benzol wurde das Gemisch, nach dem es eine Nacht stehengelassen worden war, gefiltert, das Lösungsmittel durch Destillation entfernt und der Rückstand bei reduziertem Druck unter Sammeln des Produktes fraktioniert, das bei einer Temperatur von 227 bis 229 0C bei 9 mm Hg-Druck destilliert und dem o-(/?-Diäthylaminoäthoxy)-ro-phenyl-w-äthylacetophenon entspricht.0.1 mol of o-hydroxy-w-phenyl-w-ethylacetophenone sodium salt and 0.2 mol / I-chloroethyl diethylamine were brought to the boiling point and kept at this temperature for about 2 hours. After adding 250 cm 3 of benzene, the mixture, after it had been left to stand for one night, was filtered, the solvent was removed by distillation and the residue was fractionated under reduced pressure while collecting the product, which was at a temperature of 227 to 229 0 C at 9 mm Hg pressure distilled and the o - (/? - diethylaminoethoxy) -ro-phenyl-w-äthylacetophenon corresponds.

Mit demselben Verfahren wurde auch das ο-(β-ΌΊ-methylamino-äthoxy)-e>-phenyl-«>-äthylacetophenon bei einer Temperatur von 195 bis 198°C bei 10 mm Hg-Druck hergestellt.Using the same process, ο- (β-ΌΊ- methylamino-ethoxy) -e> -phenyl - «> - ethylacetophenone was produced at a temperature of 195 to 198 ° C at 10 mm Hg pressure.

Bei spiel 4Example 4

In 50 cm3 wasserfreiem Äther wurden 0,1 Mol ο - (ß - Diäthylaminoäthoxy) - 3r- phenyl - propiophenon gelöst und eine Lösung aus 50 cm3 mit Chlorwasserstoffgas gesättigtem Äther zugesetzt.0.1 mol of ο - (ß - diethylaminoethoxy) - 3r-phenyl - propiophenone were dissolved in 50 cm 3 of anhydrous ether and a solution of 50 cm 3 of ether saturated with hydrogen chloride gas was added.

Nach Abkühlen und einer anschließenden Ruhezeit kristallisiert das Chlorhydrat von o-(/i-Diäthylaminoäthoxy)-3-phenyl-propiophenon in kleinen weißen Nadeln mit einem Schmelzpunkt von 128 bis 129°C aus Äthanol aus.After cooling and a subsequent rest period, the hydrochloride of o - (/ i-diethylaminoethoxy) -3-phenyl-propiophenone crystallizes in small white needles with a melting point of 128 to 129 ° C from ethanol.

Mit demselben Verfahren werden folgende weitere Chlorhydrate hergestellt:The following additional chlorine hydrates are produced using the same process:

4 a) Chlorhydrat von o-(/f-DimethyIaminoäthoxy)-3-phenylpropiophenon (Schmelzpunkt 164 bis4 a) Chlorohydrate of o - (/ f-DimethyIaminoäthoxy) -3-phenylpropiophenon (Melting point 164 to

165°C),
4 b) Chlorhydrat von o-(/i-Dimethylaminoäthoxy)- «)-phenyl-«-äthylacetophenon (Schmelzpunkt
165 ° C),
4 b) Hydrochloride of o - (/ i-dimethylaminoethoxy) - «) -phenyl -« - ethylacetophenone (melting point

95 bis 98 0C),
4 c) Chlorhydrat von o-(/J-Diäthylaminoäthoxy)-fo-phenyl-w-äthylacetophenon (Schmelzpunkt 88 bis 89°C).
95 to 98 0 C),
4 c) hydrochloride of o - (/ I-diethylaminoethoxy) -fo-phenyl-w-ethylacetophenone (melting point 88 to 89 ° C).

Rückfluß erhitzt. Nach Abkühlung fiel das Jodmethylat des o-(/?-Dimethyläminoäthoxy)-r«-phenylco-äthylacetophenons mit einem Schmelzpunkt von 0C aus Äthanol aus.Heated to reflux. After cooling, the iodine methylate of o - (/? - dimethylaminoethoxy) -r «-phenylco-ethylacetophenone with a melting point of 0 ° C. precipitated from ethanol.

Mit demselben Verfahren werden auch folgende quaternären Salze hergestellt:The following quaternary salts are also produced using the same process:

5 a) Jodmethylat von o-(ß-Dimethylaminoäthoxy)-5 a) iodine methylate of o- (ß-dimethylaminoethoxy) -

3-phenylpropiophenon (Schmelzpunkt 140f' C), 5 b) Jodmethylat von o-(/^Dimethylammoäthoxy)-3-phenylpropiophenon (Schmelzpunkt 123 bis3-phenylpropiophenone (melting point 140 f 'C), 5 b) of Jodmethylat o - (/ ^ Dimethylammoäthoxy) -3-phenylpropiophenone (melting point 123 to

125°C),
5 c) Jodäthylat von o-(/i-Dimethylaminoäthoxy)-
125 ° C),
5 c) iodine ethylate of o - (/ i-dimethylaminoethoxy) -

3-phenylpropiophenon (Schmelzpunkt 1220C), 5d) Jodmethylat von o-(/J-Diäthylaminoäthoxy)-fo-phenyl-(u-äthylacetophenon (Schmelzpunkt3-phenylpropiophenone (melting point 122 0 C), 5d) Jodmethylat of o - (/ J-Diäthylaminoäthoxy) -fo-phenyl- (u-äthylacetophenon (melting point

65°C),
5 e) Jodäthylat von ο - (β - Diäthylaminoäthoxy)-w-phenyl-cu-äthylacetophenon (Schmelzpunkt 91 bis 92°C).
65 ° C),
5 e) Iodoethylate of ο - (β - diethylaminoethoxy) -w-phenyl-cu-ethylacetophenone (melting point 91 to 92 ° C).

Claims (1)

Patentanspruch:Claim: Verfahren zur Herstellung'von o-(ß-Dialkylaminoäthoxy) - phenylketonen der allgemeinen FormelProcess for the production of o- (ß-dialkylaminoethoxy) - phenyl ketones of the general formula 4040 4545 B e ispie1 5Example 5 0,1 Mol o-(/i-Dimethylaminoäthoxy)-f;-phenyl-(o-äthylacetophenon wurde in 50 cm3 Methylalkohol gelöst und 0,3 Mol Methyljodid zugesetzt. Die Mischung wurde während einiger Stunden unter0.1 mol of o- (/ i-dimethylaminoethoxy) -f; -phenyl- (o-ethylacetophenone was dissolved in 50 cm 3 of methyl alcohol and 0.3 mol of methyl iodide was added OR'OR ' worin R den Methyl-, den /i-Phenyläthyl- oder den (x-Phenyl-n-propylrest und R' den ^-Dimethyl· aminoäthyl- oder den /i-Diäthylaminoäthylrest bedeutet, und deren Säureadditionssalzen und quartären Salzen, dadurch gekennzeichnet, daß man in an sich bekannter Weise entsprechende /f-Dialkylaminoäthylhalogenide oder deren halogenwasserstoffsaure Salze mit den entsprechenden o-Hydroxy-phenylketonen umsetzt und die erhaltenen Basen gegebenenfalls in Säureadditionssalze oder quartäre Salze überführt. wherein R denotes the methyl, the / i-phenylethyl or the (x-phenyl-n-propyl radical and R 'den ^ -dimethyl aminoethyl or the / i-diethylaminoethyl radical means, and their acid addition salts and quaternary salts, characterized in that that corresponding / f-dialkylaminoethyl halides are used in a manner known per se or their hydrohalic acid salts with the corresponding o-hydroxyphenyl ketones and the bases obtained are optionally converted into acid addition salts or quaternary salts. In Betracht gezogene Druckschriften:
Deutsche Patentschrift Nr. 558 647;
deutsche Auslegeschrift Nr. 1063 181;
USA.-Patentschriften Nr. 2 668 850, 2 796 435.
Considered publications:
German Patent No. 558,647;
German Auslegeschrift No. 1063 181;
U.S. Patent Nos. 2,668,850, 2,796,435.
Bei der Bekanntmachung der Anmeldung ist ein Versuchsbericht mit Tabelle I (4 Blatt) ausgelegt worden.When the application was announced, a test report with Table I (4 sheets) was displayed.
DES68684A 1960-05-25 1960-05-25 Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts Pending DE1265758B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DES68684A DE1265758B (en) 1960-05-25 1960-05-25 Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DES68684A DE1265758B (en) 1960-05-25 1960-05-25 Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts

Publications (1)

Publication Number Publication Date
DE1265758B true DE1265758B (en) 1968-04-11

Family

ID=7500462

Family Applications (1)

Application Number Title Priority Date Filing Date
DES68684A Pending DE1265758B (en) 1960-05-25 1960-05-25 Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts

Country Status (1)

Country Link
DE (1) DE1265758B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569A1 (en) 2005-10-26 2011-08-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE558647C (en) * 1930-08-28 1932-09-10 Chemische Ind Ges Process for the production of basic ethers of aromatic ketones
US2668850A (en) * 1952-04-24 1954-02-09 Hoffmann La Roche Phenyl-phenethyl ketones
US2796435A (en) * 1955-02-16 1957-06-18 Hoffmann La Roche Derivatives of 4(diethylaminoethoxy)-diphenylpropane
DE1063181B (en) * 1955-02-16 1959-08-13 Hoffmann La Roche Process for the production of dialkylamino-alkyl ethers of diphenylalkanes and diphenylalkenes with fungicidal and protozoanic properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE558647C (en) * 1930-08-28 1932-09-10 Chemische Ind Ges Process for the production of basic ethers of aromatic ketones
US2668850A (en) * 1952-04-24 1954-02-09 Hoffmann La Roche Phenyl-phenethyl ketones
US2796435A (en) * 1955-02-16 1957-06-18 Hoffmann La Roche Derivatives of 4(diethylaminoethoxy)-diphenylpropane
DE1063181B (en) * 1955-02-16 1959-08-13 Hoffmann La Roche Process for the production of dialkylamino-alkyl ethers of diphenylalkanes and diphenylalkenes with fungicidal and protozoanic properties

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569A1 (en) 2005-10-26 2011-08-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US8476259B2 (en) 2005-10-26 2013-07-02 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
DE1163328B (en) Process for the preparation of 5-phenoxymethyl-oxazolidonen- (2)
DE2340873A1 (en) MORPHOLINE DERIVATIVES
DE1265758B (en) Process for the preparation of o- (beta-dialkylaminoaethoxy) phenyl ketones and their acid addition salts and quaternary salts
DE1194418B (en) Process for the production of new dihalogenamino-benzylamines or their acid addition salts with physiologically compatible acids
DE2001431A1 (en) Process for the preparation of new, therapeutically valuable derivatives of 2'-hydroxy-3-phenylpropionphenone and their salts
DE1227914B (en) Process for the preparation of 3- (1, 2-dithia-cyclopentyl) -5-pentanoic acid
DE883901C (en) Process for the preparation of quinolyl-3-dialkyl phosphates and their salts
DE2166270C3 (en) Nicotinoylaminoethanesulfonyl-2amino-thiazole
DE1468920A1 (en) Process for the preparation of new dibenzocycloheptadiene derivatives
DE1593315C (en)
DE597305C (en) Process for the preparation of aliphatic primary amino acids or their derivatives
DE1266755B (en) Process for the preparation of substituted dibenzo [a, d] -cycloheptane compounds and salts of these compounds with acids
DE2166997C3 (en) Process for the preparation of 4,4-diphenyl-piperidines
DE887649C (en) Process for the preparation of unsaturated amines suitable as antispasmodics
DE1593315B1 (en) 9-isopropylidene-9,10-dihydroanthracene-10-carboxylic acid-ß-diaethylamino-ethyl ester, their salts and process for their preparation
DE1097995B (en) Process for the preparation of phenthiazine derivatives
DE716579C (en) Process for the production of ester amides of almond acid
DE947370C (en) Process for the preparation of 4-thionylamino-2-oxy-benzoyl chloride
DE1468167B2 (en) BASIC ESTERS OF BICYCLIC DICARBONIC ACIDS, THEIR ACID ADDITIONAL SALTS AND BISQUATERNAL AMMONIUM COMPOUNDS, AND PROCESS FOR THE PREPARATION OF THE SAME
DE972261C (en) Process for the preparation of dioxopyrazolidine compounds
AT243268B (en) Process for the preparation of new benzoquinolizine derivatives
AT265530B (en) Process for the preparation of new isoquinoline derivatives
DE611692C (en) Process for the preparation of cyclically disubstituted tetrazoles
DE693090C (en) henanthroline series
DE957036C (en) Process for the production of new diammonium compounds that influence muscle tone